Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above

NCT07152639 is registered in ClinicalTrials.gov with Chengdu CoenBiotech Co., Ltd as lead sponsor.

NCT NCT07152639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07152639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Mycobacterium Tuberculosis Fusion Protein (EEC) for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
Lead sponsor
Chengdu CoenBiotech Co., Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
August 9, 2025
Completion date
July 1, 2026
Enrollment
1,784 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis